Tolvaptan

A benzazepine derivative and selective VASOPRESSIN V2 RECEPTOR antagonist that is used to treat euvolemic and hypervolemic HYPONATREMIA. It is also used in the treatment of rapidly progressing AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE to slow the rate of cyst development and renal insufficiency.

Also Known As:

Networked: 1058 relevant articles (283 outcomes, 334 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Gheorghiade, Mihai: 53 articles (01/2018 - 02/2003)
2.	Ouyang, John: 45 articles (05/2022 - 06/2003)
3.	Konstam, Marvin A: 41 articles (01/2022 - 05/2005)
4.	Torres, Vicente E: 37 articles (08/2021 - 04/2005)
5.	Czerwiec, Frank S: 32 articles (06/2020 - 11/2006)
6.	Kinugawa, Koichiro: 30 articles (01/2022 - 01/2012)
7.	Zannad, Faiez: 28 articles (01/2018 - 05/2005)
8.	Gansevoort, Ron T: 27 articles (01/2022 - 05/2011)
9.	Maggioni, Aldo P: 27 articles (01/2018 - 03/2007)
10.	Swedberg, Karl: 27 articles (01/2018 - 05/2005)

Related Diseases

1.	Heart Failure 08/01/2014 - "Marked improvement was achieved after administration of Tolvaptan for heart failure in the postoperative period. " 09/01/2010 - "However, tolvaptan has not proven to be beneficial for the long-term management of heart failure. " 09/26/2019 - "Minnesota Living with Heart Failure Questionnaire score improved significantly in the tolvaptan group (from 58 to 10, P=0.030). " 03/01/2010 - "In patients with congestive heart failure (CHF) and symptoms of volume overload, tolvaptan prompted rapid free water elimination and improved short-term signs and symptoms of HF, although no effect on long-term mortality or HF-related morbidity was observed. " 12/01/2008 - "Tolvaptan is also effective for treatment of congestive heart failure (CHF) exacerbation, but whether there are long standing beneficial effects on CHF is still controversial. "
2.	Hyponatremia 01/01/2018 - "Tolvaptan is a very effective treatment for hypervolemic or euvolemic hyponatremia. " 06/01/2016 - "There was no difference in overall neurocognitive composite scores of speed domains between groups, except for the psychomotor speed domain, which was statistically improved following hyponatremia correction with tolvaptan (treatment effect, 0.27; 95% CI, 0.04-0.51; P=0.03). " 10/01/2017 - "Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. " 06/01/2012 - "The data show that tolvaptan is effective for the treatment of hyponatremia and may produce differing responses in disparate patient groups." 04/01/2010 - "Oral tolvaptan is safe and effective in chronic hyponatremia."
3.	Autosomal Dominant Polycystic Kidney (ADPKD) 01/01/2022 - "Further advancing compound 25 in a murine model of ADPKD demonstrated a significantly improved in vivo efficacy compared with the reference compound tolvaptan. " 03/01/2021 - "A year treatment with tolvaptan significantly improved %TKV in patients with ADPKD, regardless of the gene mutation type." 01/01/2020 - "Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD." 12/01/2018 - "This analysis indicates that the efficacy of tolvaptan for Japanese patients with later stage ADPKD was not significantly different from that of Japanese patients with earlier stage ADPKD." 05/01/2008 - "A phase 3, placebo-controlled, double-blind study in 18- to 50-yr-old patients with autosomal dominant polycystic kidney disease and preserved renal function but relatively rapid progression, as indicated by a total kidney volume >750 ml, has been initiated and will determine whether tolvaptan is effective in slowing down the progression of this disease."
4.	Ascites 01/01/2020 - "The aim of this meta-analysis was to evaluate whether response to treatment with tolvaptan is associated with improved overall survival in cirrhotic patients with refractory ascites. " 11/01/2015 - "We evaluated the therapeutic efficacy and safety of tolvaptan administration to treat refractory ascites. " 11/01/2013 - "Tolvaptan had therapeutic efficacy in the reduction of ascites in rats with chronic liver injury. " 12/01/2021 - "In this study, we conducted a genome-wide association study (GWAS) in the Japanese population to identify genetic variants associated with tolvaptan's efficacy for patients with hepatic ascites. " 04/01/2019 - "Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites."
5.	Inappropriate ADH Syndrome (SIADH) 11/06/2017 - "This study confirms the safety and efficacy of Tolvaptan in the treatment of SIADH-related significant, symptomatic hyponatraemia when used under specialist guidance and strict monitoring. " 11/01/2018 - "Tolvaptan could be a good, safe, and effective treatment option in pediatric SIADH cases that are resistant to treatment. " 11/01/2018 - "Here we present a pediatric case of SIADH that was resistant to treatment with fluid restriction and hypertonic saline infusion and was treated successfully with tolvaptan. " 07/01/2020 - "Tolvaptan at a moderate dose is more effective than fluid restriction in the treatment of SIADH. " 10/17/2023 - "This case report represents the first documented evidence of the therapeutic efficacy of tolvaptan in treating SIADH in a dog."

Related Drugs and Biologics

1.	Vasopressins (Vasopressin)
2.	Sodium
3.	Vasopressin Receptors (Arginine Vasopressin Receptor)
4.	Diuretics
5.	Furosemide (Lasix)
6.	Antidiuretic Hormone Receptor Antagonists
7.	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)
8.	conivaptan (Vaprisol)
9.	Creatinine
10.	lixivaptan

Related Therapies and Procedures

1.	Therapeutics
2.	Patient Readmission
3.	Length of Stay
4.	Drug Therapy (Chemotherapy)
5.	Hepatectomy